# Molecular Effect of Tobacco on Genetic, Epigenetic, and Metabolic Pathways During Cancer Progression

**Authors:** Ujjwal Kumar, G Jahnavi, Bijit Biswas, Benazir Alam, Saurabh Varshney

PMC · DOI: 10.7759/cureus.102757 · Cureus · 2026-01-31

## TL;DR

This study explores how tobacco affects genes, epigenetics, and metabolism to promote cancer and other diseases, offering insights for targeted treatments and public health strategies.

## Contribution

The paper uniquely integrates molecular disruptions from tobacco, emphasizing novel insights into metabolic reprogramming and epigenetic mechanisms in tobacco-induced pathogenesis.

## Key findings

- Tobacco exposure downregulates tumor suppressor genes like P53 and ATM, leading to genomic instability and increased cancer risk.
- Tobacco disrupts metabolic pathways through CYP2A6, MTHFR, and HIF-1α, contributing to insulin resistance and mitochondrial dysfunction.
- Epigenetic changes via HDAC1 and EZH2 silence tumor suppressors like CDKN2A, creating long-term oncogenic imprints.

## Abstract

Tobacco consumption remains a leading global health challenge, driving chronic diseases such as cancer, cardiovascular disorders, and metabolic dysfunction through intricate molecular mechanisms. This study investigates the multifaceted effects of tobacco exposure on genetic, epigenetic, and metabolic pathways, focusing on its role in carcinogenesis. Tobacco smoke, laden with carcinogens like benzopyrene, nitrosamines, and reactive oxygen species (ROS), induces genetic mutations and impairs DNA repair by downregulating tumor suppressor genes like tumor protein 53 (P53), ataxia-telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), and poly (ADP-ribose) polymerase 1 (PARP1), leading to genomic instability and heightened cancer risk. Dysregulation of apoptosis-regulating genes B-cell lymphoma 2 (BCL-2), CL2 associated X (BAX), and cysteinyl aspartate specific proteinase 3 and 9 (CASPASE-3, CASPASE-9) further promotes tumor cell survival, while nicotine addiction genes cholinergic receptor nicotinic beta 3 subunit (CHRNB3), dopamine receptor D2 (DRD2), catechol-O-methyltransferase (COMT), and dopamine beta-hydroxylase (DBH) reinforce dependency via dopaminergic pathways. Metabolically, tobacco disrupts glycolysis, oxidative phosphorylation, and folate metabolism by altering cytochrome P450 family 2 subfamily A member 6 (CYP2A6), methylenetetrahydrofolate reductase (MTHFR), and hypoxia-inducible factor 1-alpha (HIF-1α) expression, resulting in insulin resistance, mitochondrial dysfunction, and lipid peroxidation, which exacerbate systemic diseases and cancer progression (Warburg effect). Epigenetic changes, including DNA methylation and histone modifications via histone deacetylase 1 (HDAC1), enhancer of zeste 2 polycomb repressive complex 2 subunits (EZH2), and suppressor of variegation 3-9 homolog 1 (SUV39H1), silence tumor suppressors cyclin-dependent kinase inhibitor 2A (CDKN2A), creating a long-term oncogenic imprint. Mitochondrial genes, mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 1 & 4 (MT-ND1 and MT-ND4) and mitochondrially encoded cytochrome c oxidase I (MT-CO1), suffer, reducing ATP synthesis and increasing ROS, which drives apoptosis evasion and inflammatory nuclear factor kappa B (NF-κB), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α). This research uniquely integrates these molecular disruptions, emphasizing novel insights into metabolic reprogramming (CYP2A6, MTHFR, HIF-1α) and epigenetic mechanisms in tobacco-induced pathogenesis. Additionally, it explores impacts on stem cell genes, SRY-box transcription factor 2 (SOX2), octamer-binding transcription factor 4 (OCT4), and Nanog homeobox (NANOG), linking tobacco to cancer stem cell proliferation and metastasis (e.g., oral squamous cell carcinoma). The study also highlights tobacco’s role in aging, telomere shortening - telomerase reverse transcriptase (TERT downregulation) - and thymic involution, accelerating immunosenescence and disease susceptibility. These findings underscore the need for targeted interventions, such as epigenetic therapies, metabolic reprogramming, and robust tobacco control policies, to mitigate the global burden of tobacco-related diseases. By providing a unified framework for understanding tobacco’s molecular impact, this research advocates for precision medicine and public health strategies to address the pervasive effects of tobacco on human health.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], ATM (ATM serine/threonine kinase) [NCBI Gene 472], ATR (ATR checkpoint kinase) [NCBI Gene 545], PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], Casp3 (caspase 3) [NCBI Gene 12367], Casp9 (caspase 9) [NCBI Gene 12371], CHRNB3 (cholinergic receptor nicotinic beta 3 subunit) [NCBI Gene 1142], DRD2 (dopamine receptor D2) [NCBI Gene 1813], COMT (catechol-O-methyltransferase) [NCBI Gene 1312], DBH (dopamine beta-hydroxylase) [NCBI Gene 1621], CYP2A6 (cytochrome P450 family 2 subfamily A member 6) [NCBI Gene 1548], MTHFR (methylenetetrahydrofolate reductase) [NCBI Gene 4524], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], HDAC1 (histone deacetylase 1) [NCBI Gene 3065], EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146], SUV39H1 (SUV39H1 histone lysine methyltransferase) [NCBI Gene 6839], CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], ND1 (NADH dehydrogenase subunit 1) [NCBI Gene 4535], ND4 (NADH dehydrogenase subunit 4) [NCBI Gene 4538], COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], IL6 (interleukin 6) [NCBI Gene 3569], TNF (tumor necrosis factor) [NCBI Gene 7124], SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657], POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460], NANOG (Nanog homeobox) [NCBI Gene 79923], TERT (telomerase reverse transcriptase) [NCBI Gene 7015]
- **Diseases:** cancer (MONDO:0004992), oral squamous cell carcinoma (MONDO:0004958)

## Full-text entities

- **Genes:** PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, PMP22 (peripheral myelin protein 22) [NCBI Gene 5376] {aka CIDP, CMT1A, CMT1E, DSS, GAS-3, GAS3}, pyruvate kinase [NCBI Gene 107797877], TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MTHFR [NCBI Gene 107808152], hexokinase [NCBI Gene 107797523], COMT [NCBI Gene 107795225], PERP (p53 apoptosis effector related to PMP22) [NCBI Gene 64065] {aka EKVP7, KCP1, KRTCAP1, OLMS2, PIGPC1, THW}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, cytochrome C [NCBI Gene 107816090], beta4 [NCBI Gene 107794572], TERT [NCBI Gene 107815112], beta2 [NCBI Gene 107778362], Catechol-O-methyltransferase [NCBI Gene 107788038], PI3K [NCBI Gene 107795370], alpha10 [NCBI Gene 107832044], H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}
- **Diseases:** nicotine (MESH:D014029), neurodegeneration (MESH:D019636), chronic inflammation (MESH:D007249), osteosarcoma (MESH:D012516), small cell lung cancer (MESH:D055752), TEC (MESH:C536980), dyslipidemia (MESH:D050171), addictive behaviors (MESH:D000437), muscle-invasive cancers (MESH:D019042), Mitochondrial dysfunction (MESH:D028361), Pancreatic cancer (MESH:D010190), psychiatric diseases (MESH:D001523), addiction (MESH:D019966), fibrosarcoma (MESH:D005354), lung cancer (MESH:D008175), endothelial dysfunction (MESH:D014652), lung and heart problems (MESH:D008171), Cancer (MESH:D009369), Head and neck cancers (MESH:D006258), Metabolic disruptions (MESH:D019958), esophageal squamous carcinoma (MESH:D000077277), nausea (MESH:D009325), autoimmune diseases (MESH:D001327), organ dysfunction (MESH:D009102), tobacco addicted (OMIM:188890), smoking (MESH:D015208), obesity (MESH:D009765), hypoxic (MESH:D002534), carcinogenesis (MESH:D063646), metabolic disorders (MESH:D008659), marijuana (MESH:D000074609), oral squamous cell carcinoma (MESH:D000077195), non-small cell lung cancer (MESH:D002289), systemic diseases (MESH:D034721), metastasis (MESH:D009362), carcinogenic (MESH:D011230), deaths (MESH:D003643), cardiovascular diseases (MESH:D002318), infections (MESH:D007239), immune deficits (MESH:D007154), ataxia telangiectasia (MESH:D001260), insulin resistance (MESH:D007333), dizziness (MESH:D004244), inflammatory cytokines (MESH:D000080424), thymic atrophy (MESH:D013953), bacterial infections (MESH:D001424), immune system dysregulation (OMIM:614878), hepatocellular carcinoma (MESH:D006528), Esophageal cancer (MESH:D004938), leukoplakia (MESH:D007971), Bladder cancer (MESH:D001749), chronic (MESH:D002908), breast, prostate, endometrial, and brain tumors (MESH:D011472)
- **Chemicals:** succinate (MESH:D019802), B[a]P (MESH:D001564), ammonia (MESH:D000641), oxygen (MESH:D010100), carbon monoxide (MESH:D002248), cortisol (MESH:D006854), nitrogen (MESH:D009584), guanine (MESH:D006147), tricarboxylic acid (MESH:D014233), 4(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (MESH:C016583), carbon (MESH:D002244), epinephrine (MESH:D004837), cytosine (MESH:D003596), Benzene (MESH:D001554), phospholipid (MESH:D010743), free radicals (MESH:D005609), cardiolipin (MESH:D002308), polycyclic hydrocarbons (MESH:D006844), hydrogen cyanide (MESH:D006856), polonium (MESH:D011059), Ach (MESH:D000109), NA (MESH:D009638), GABA (MESH:D005680), alkaloids (MESH:D000470), adenine (MESH:D000225), glutamate (MESH:D018698), N-nitrosamines (MESH:D009602), hydroxyl radicals (MESH:D017665), PAH (MESH:D011084), tyramine (MESH:D014439), superoxide (MESH:D013481), trans-3'-hydroxy-cotinine (MESH:C001381), Ca2+ (-), caffeine (MESH:D002110), catecholamines (MESH:D002395), reactive nitrogen species (MESH:D026361), homocysteine (MESH:D006710), TCA (MESH:D014238), amine (MESH:D000588), 1-methyl-2-[3pyridyl]pyrrolidine (MESH:D009538), ATP (MESH:D000255), lipid (MESH:D008055), benzopyrene (MESH:D001580), lead (MESH:D007854), nicotinamide adenine dinucleotide (MESH:D009243), dopamine (MESH:D004298), alcohol (MESH:D000438), hydrogen (MESH:D006859), arsenic (MESH:D001151), cotinine (MESH:D003367), formaldehyde (MESH:D005557), 5-HT (MESH:D012701), polonium-210 (MESH:C000615141), glucose (MESH:D005947), barium (MESH:D001464), folate (MESH:D005492), ROS (MESH:D017382), calcium (MESH:D002118)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** tyrosine through tyrosine, CC to TT, T) at position 32806, G --> T, C677T
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), 547 — Homo sapiens (Human), Ovarian serous adenocarcinoma, Cancer cell line (CVCL_6562), A459 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_JR68)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12954342/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12954342/full.md

## References

156 references — full list in the complete paper: https://tomesphere.com/paper/PMC12954342/full.md

---
Source: https://tomesphere.com/paper/PMC12954342